Shares of Valeant Pharmaceuticals International Inc. (NYSE:VRX) saw strong trading volume on Thursday . 32,296,889 shares traded hands during trading, an increase of 26% from the previous session’s volume of 25,730,472 shares.The stock last traded at $23.09 and had previously closed at $23.06.

Several analysts recently weighed in on the company. Guggenheim restated a “buy” rating and set a $55.00 target price (down previously from $145.00) on shares of Valeant Pharmaceuticals International in a research note on Saturday, March 19th. Rodman & Renshaw restated a “buy” rating on shares of Valeant Pharmaceuticals International in a research note on Sunday, April 3rd. Wells Fargo & Co. restated a “sell” rating on shares of Valeant Pharmaceuticals International in a research note on Saturday, April 9th. BMO Capital Markets restated a “positive” rating on shares of Valeant Pharmaceuticals International in a research note on Friday, April 29th. Finally, Piper Jaffray Cos. restated a “sell” rating on shares of Valeant Pharmaceuticals International in a research note on Sunday, May 29th. Seven investment analysts have rated the stock with a sell rating, fifteen have issued a hold rating, ten have assigned a buy rating and one has assigned a strong buy rating to the stock. The company has a consensus rating of “Hold” and an average target price of $74.71.

The stock’s 50 day moving average price is $24.10 and its 200-day moving average price is $52.43. The company’s market cap is $7.98 billion.

Valeant Pharmaceuticals International (NYSE:VRX) last issued its quarterly earnings results on Tuesday, June 7th. The specialty pharmaceutical company reported $1.27 EPS for the quarter, missing the Zacks’ consensus estimate of $1.37 by $0.10. The business had revenue of $2.37 billion for the quarter, compared to analyst estimates of $2.34 billion. The company’s revenue was up 9.3% on a year-over-year basis. During the same quarter in the prior year, the business earned $2.36 earnings per share. On average, analysts expect that Valeant Pharmaceuticals International Inc. will post $6.62 EPS for the current year.

In other news, CEO Joseph C. Papa purchased 202,000 shares of the business’s stock in a transaction on Friday, June 10th. The shares were acquired at an average price of $24.48 per share, with a total value of $4,944,960.00. Following the completion of the transaction, the chief executive officer now owns 2,442,199 shares of the company’s stock, valued at approximately $59,785,031.52. The purchase was disclosed in a filing with the SEC, which can be accessed through the SEC website.

Other hedge funds have recently modified their holdings of the company. Oppenheimer & Co. Inc. boosted its stake in shares of Valeant Pharmaceuticals International by 51.2% in the fourth quarter. Oppenheimer & Co. Inc. now owns 10,455 shares of the specialty pharmaceutical company’s stock worth $1,062,000 after buying an additional 3,541 shares during the period. PNC Financial Services Group Inc. boosted its stake in shares of Valeant Pharmaceuticals International by 95.4% in the fourth quarter. PNC Financial Services Group Inc. now owns 127,715 shares of the specialty pharmaceutical company’s stock worth $12,982,000 after buying an additional 62,361 shares during the period. New York State Common Retirement Fund boosted its stake in shares of Valeant Pharmaceuticals International by 64.4% in the fourth quarter. New York State Common Retirement Fund now owns 276,226 shares of the specialty pharmaceutical company’s stock worth $28,078,000 after buying an additional 108,175 shares during the period. Academy Capital Management Inc. TX purchased a new stake in shares of Valeant Pharmaceuticals International during the fourth quarter worth approximately $7,102,000. Finally, OppenheimerFunds Inc. boosted its stake in shares of Valeant Pharmaceuticals International by 14.1% in the fourth quarter. OppenheimerFunds Inc. now owns 611,772 shares of the specialty pharmaceutical company’s stock worth $62,186,000 after buying an additional 75,705 shares during the period.

Valeant Pharmaceuticals International, Inc is a specialty pharmaceutical and medical device company. The Company is engaged in developing, manufacturing, and marketing a range of branded, generic and branded generic pharmaceuticals, over-the-counter (OTC) products, and medical devices (contact lenses, intraocular lenses, ophthalmic surgical equipment, and aesthetics devices), which are marketed directly or indirectly in over 100 countries.